Feed NVS
NV

Novartis

NVS · NYSE

$144.54 +0.68% (+$0.97)
1M -8.87%
Market Cap $272.9B
P/E Ratio 21.39x
Div. Yield 3.30%
ROE 29.93%

Bulios Fair Price

$139.69

3.4% downside

Current Price

$144.54

Undervalued Fair Value Overvalued

According to Bulios Fair Price, NVS is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
56 /100
Fair
P/E 21.39x
EV/EBITDA 14.12x
PEG 1.10x
Growth
69 /100
Growing
EPS growth 31.39%
Rev. growth 8.04%
Book val. growth 8.05%
Profitability
100 /100
Strong
Gross margin 74.44%
Net margin 22.93%
FCF margin 28.43%
Quality
79 /100
Excellent
ROIC 13.93%
ROE 29.93%
Asset turnover 0.46x
Debt
61 /100
Moderate
Debt/Equity 1.18x
Current ratio 0.86x
Net debt/EBITDA 1.86x
Stability
64 /100
Moderate
Beta 0.46x
Rev. volatility 2.51%
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NVS
Online

About the company

Novartis AG is a Swiss global pharmaceutical company with a broad portfolio of medicines and healthcare products. The company is one of the leading players in the pharmaceutical industry and operates worldwide. Novartis focuses on the development, manufacturing, and distribution of innovative medicines in various therapeutic areas, including oncology, cardiology, ophthalmology, neurology, and others. The company also specializes in the production and sale of generic drugs. Novartis dedicates significant efforts to research and development of new treatment options to help improve the quality of life for patients around the world. The company actively collaborates with medical professionals and institutions to ensure the best care for patients. Novartis AG (NVS) shares are an attractive choice for investors who follow the pharmaceutical industry and seek investment opportunities in a reputable company with a rich medical portfolio and a long history of innovation.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Vasant Narasimhan

Employees

75,267

Headquarters

Basel

Upcoming events

27 OCT

Earnings

Upcoming earnings report

32d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.